26th Apr 2019 12:29
LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said its Parsortix system has been used in "groundbreaking" cancer research.
The research showed the first the time the role of myeloid-derived suppressor cells as part of large circulating tumour cells, which are 50 times more likely to metastasise than single tumour cells.
Metastasis is when cancer spreads to other sites in the body, usually via the blood, and causes 90% of all cancer-related deaths.
Myeloid-derived suppressor cells, Angle said, play a key role in metastasis by suppressing the immune system and strengthening tumour cells.
"A key finding was that, when circulating tumour cells were cultured, the addition of myeloid-derived suppressor cells lead to an increase in the number of circulating tumour cells by a factor of ten compared to a control circulating tumour cells culture without the addition," said Angle.
Angle said the research was carried out at the Biomarker Research Program at Houston Methodist Research Institute, alongside the University of Texas' Center for Precision Health and MD Anderson Cancer Center.
Anglo Founder & Chief Executive Andrew Newland commented: "Investigation into circulating tumour cells clusters and their impact on metastasis, an area where Angle's Parsortix system is strongly differentiated, is beginning to take off with further seminal work by another one of Angle's leading customers."
"This work identifies the role of immune suppressor cells within the circulating tumour cells cluster highlighting key new areas for drug development with the potential for Parsortix to be routinely used as a companion diagnostic. Our ultimate aim is for the Parsortix system to be routinely used for all cancer patients in the future."
Angle shares were 4.7% higher on Friday at a price of 71.75 pence each.
Related Shares:
Angle